<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39355057</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1179-1594</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Risk management and healthcare policy</Title><ISOAbbreviation>Risk Manag Healthc Policy</ISOAbbreviation></Journal><ArticleTitle>Biosafety Management Based Upon Risk Assessment and Monitoring: Perspectives from a Clinical Laboratory, China.</ArticleTitle><Pagination><StartPage>2291</StartPage><EndPage>2303</EndPage><MedlinePgn>2291-2303</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/RMHP.S476005</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVE" NlmCategory="UNASSIGNED">Inadequate risk assessment and a lack of risk monitoring are common deficiencies in clinical laboratory, and are also the main causes of biosafety incidents. Therefore, we summarized the experience of implementing adequate risk assessment and maintaining risk monitoring, and established a procedure for continuously improving biosafety management.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Learning from our laboratory's experience in implementing risk assessment, risk response, and risk monitoring before and during the COVID-19 epidemic, we summarized the procedures for fully identifying risks, accurately evaluating risks, maintaining risk monitoring, establishing and regular reviewing safety indicators. On this basis, we established a system for continuously improving biosafety management through risk monitoring and reviewing safety indicator.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">We identified a total of 30 unacceptable risks prior to the COVID-19 pandemic, and developed and implemented appropriate risk control measures. After risk control, residual risks were acceptable, and no biosafety incidents have occurred. During the COVID-19 pandemic, after multiple risk monitoring, we identified ten new risks, three ineffective risk control measures, and multiple control measures for excessive protection. Then, we timely adjusted risk control measures to avoid laboratory personnel infection and excessive protection. Meanwhile, We established eight safety indicators and identified two improvement opportunities through regular reviews.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Adequate risk identification and accurate risk assessment are particularly important for effectively controlling biosafety risks. Biosafety management should be continuously improved to deal with ineffective and excessive protection caused by various changes in experimental activities. Continuous improvement of biosafety management can be achieved through risk monitoring, regular review of safety indicators, and management reviews. This study will help laboratory managers to fully and accurately assess risks, as well as update risks and their control measures through risk monitoring, and the continuous improvement procedure established in the study has certain reference value for laboratories to effectively respond to emerging infectious diseases and avoid excessive protection.</AbstractText><CopyrightInformation>© 2024 Diao et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Diao</LastName><ForeName>Qizhi</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0003-1121-4656</Identifier><AffiliationInfo><Affiliation>Hainan Branch, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Sanya, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Yongpei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The People's Hospital of Jianyang City, Sichuan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Fangyu</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory Medicine, University-Town Hospital of Chongqing Medical University, Chongqing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nong</LastName><ForeName>Cuihui</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0003-8845-7952</Identifier><AffiliationInfo><Affiliation>Hainan Branch, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Sanya, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Huamiao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Hainan Branch, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Sanya, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xiangmin</ForeName><Initials>X</Initials><Identifier Source="ORCID">0009-0008-2557-3522</Identifier><AffiliationInfo><Affiliation>Hainan Branch, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Sanya, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Guoqiang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Chong Qing King Med Center for Clinical Laboratory Co., Ltd, Chongqing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>The Sixth People's Hospital of Chongqing, Chongqing, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Risk Manag Healthc Policy</MedlineTA><NlmUniqueID>101566264</NlmUniqueID><ISSNLinking>1179-1594</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">biosafety management</Keyword><Keyword MajorTopicYN="N">continuous improvement</Keyword><Keyword MajorTopicYN="N">management review</Keyword><Keyword MajorTopicYN="N">risk assessment</Keyword><Keyword MajorTopicYN="N">risk monitoring</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>7</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>7</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>4</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39355057</ArticleId><ArticleId IdType="pmc">PMC11444055</ArticleId><ArticleId IdType="doi">10.2147/RMHP.S476005</ArticleId><ArticleId IdType="pii">476005</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Landelle C, Birgand G, Price JR, et al. Considerations for de-escalating universal masking in healthcare centers. Antimicrob Steward Healthc Epidemiol. 2023;3(1):e128. doi:10.1017/ash.2023.200</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ash.2023.200</ArticleId><ArticleId IdType="pmc">PMC10428150</ArticleId><ArticleId IdType="pubmed">37592969</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornish NE, Anderson NL, Arambula DG, et al. Clinical laboratory biosafety gaps: lessons learned from past outbreaks reveal a path to a safer future. Clin Microbiol Rev. 2021;34(3):e0012618. doi:10.1128/CMR.00126-18</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00126-18</ArticleId><ArticleId IdType="pmc">PMC8262806</ArticleId><ArticleId IdType="pubmed">34105993</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin YH, Huang Q, Wang YY, et al. Perceived infection transmission routes, infection control practices, psychosocial changes, and management of COVID-19 infected healthcare workers in a tertiary acute care hospital in Wuhan: a cross-sectional survey. Mil Med Res. 2020;7(1):24. doi:10.1186/s40779-020-00254-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40779-020-00254-8</ArticleId><ArticleId IdType="pmc">PMC7211983</ArticleId><ArticleId IdType="pubmed">32393381</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Laboratory Biosafety Manual. fourth ed. Geneva [Switzerland]: WHO Press; 2020.</Citation></Reference><Reference><Citation>Kampf G, Todt D, Pfaender S, et al. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020;104(3):246–251. doi:10.1016/j.jhin.2020.01.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhin.2020.01.022</ArticleId><ArticleId IdType="pmc">PMC7132493</ArticleId><ArticleId IdType="pubmed">32035997</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng SQ, Peng HJ. Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. J Clin Med. 2020;9(2):575. doi:10.3390/jcm9020575</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9020575</ArticleId><ArticleId IdType="pmc">PMC7074453</ArticleId><ArticleId IdType="pubmed">32093211</ArticleId></ArticleIdList></Reference><Reference><Citation>Radoshitzky SR, Iversen P, Lu X, et al. Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro. Sci Rep. 2023;13(1):3131. doi:10.1038/s41598-023-29517-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-29517-9</ArticleId><ArticleId IdType="pmc">PMC9950143</ArticleId><ArticleId IdType="pubmed">36823196</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudrik JT, Soehnlen MK, Perry MJ, et al. Safety and accuracy of matrix-assisted laser desorption ionization–time of flight mass spectrometry for identification of highly pathogenic organisms. J Clin Microbiol. 2017;55(12):3513–3529. doi:10.1128/JCM.01023-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01023-17</ArticleId><ArticleId IdType="pmc">PMC5703816</ArticleId><ArticleId IdType="pubmed">29021156</ArticleId></ArticleIdList></Reference><Reference><Citation>Drevinek M, Dresler J, Klimentova J, et al. Evaluation of sample preparation methods for MALDI‐TOF MS identification of highly dangerous bacteria. Lett Appl Microbiol. 2012;55(1):40–46. doi:10.1111/j.1472-765X.2012.03255.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1472-765X.2012.03255.x</ArticleId><ArticleId IdType="pubmed">22512320</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham SA, Patel R. Standard matrix-assisted laser desorption ionization–time of flight mass spectrometry reagents may inactivate potentially hazardous bacteria. J Clin Microbiol. 2015;53(8):2788. doi:10.1128/JCM.00957-15</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00957-15</ArticleId><ArticleId IdType="pmc">PMC4508459</ArticleId><ArticleId IdType="pubmed">26019211</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackelsberg J, Liddicoat A, Burke T, et al. Brucella exposure risk events in 10 clinical laboratories, New York City, USA, 2015 to 2017. J Clin Microbiol. 2020;58(2):e01096–19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6989065</ArticleId><ArticleId IdType="pubmed">31694974</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health of the People’s Republic of China.WS/T 367-2012 Regulation of disinfection technique in healthcare settings [S]. Beijing: Standards Press of China, 2012. Available from:
http://www.nhc.gov.cn/zwgkzt/s9496/201204/54510/files/2c7560199b9d42d7b4fce28eed1b7be0.PDF. Accessed September
16, 2024.</Citation></Reference><Reference><Citation>Ministry of Housing and Urban-Rural Development of the People’s Republic of China, General Administration of Quality Supervision, Inspection and Quarantine of the People’s Republic of China. GB 50346-2011Architectural and technical code for biosafety laboratories[S]. Beijing China Architecture and Building Press, 2011. Available from:
https://www.gongbiaoku.com/read/22y18582e03?secId=prt807975at3. Accessed September
16, 2024.</Citation></Reference><Reference><Citation>National Health Commission of the People’s Republic of China. The testing work manual of novel coronavirus nucleic acid for medical institutions. Available from:
http://www.nhc.gov.cn/yzygj/s7659/202012/b89bcd0813da41788688eb14787b3c72.html. Accessed September
16, 2024.</Citation></Reference><Reference><Citation>Diarra B, Safronetz D, Sarro YDS, et al. Laboratory response to 2014 Ebola virus outbreak in Mali. J Infect Dis. 2016;214(suppl 3):S164–S168. doi:10.1093/infdis/jiw200</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw200</ArticleId><ArticleId IdType="pmc">PMC5050465</ArticleId><ArticleId IdType="pubmed">27707892</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarbrough ML, Kwon JH, Wallace MA, et al. Frequency of instrument, environment, and laboratory technologist contamination during routine diagnostic testing of infectious specimens. J Clin Microbiol. 2018;56(6):e00225–18. doi:10.1128/JCM.00225-18</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00225-18</ArticleId><ArticleId IdType="pmc">PMC5971558</ArticleId><ArticleId IdType="pubmed">29563204</ArticleId></ArticleIdList></Reference><Reference><Citation>Biedron C, Lyman M, Stuckey MJ, et al. Evaluation of infection prevention and control readiness at frontline health care facilities in high-risk districts bordering Ebola virus disease-affected areas in the democratic republic of the Congo - Uganda, 2018. MMWR Morb Mortal WklyRep. 2019;68(39):851–854. doi:10.15585/mmwr.mm6839a4</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6839a4</ArticleId><ArticleId IdType="pmc">PMC6776373</ArticleId><ArticleId IdType="pubmed">31581162</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng H, Bilal M, Iqbal HMN. Improved biosafety and biosecurity measures and/or strategies to tackle laboratory-acquired infections and related risks. Int J Environ Res Public Health. 2018;15(12):2697. doi:10.3390/ijerph15122697</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph15122697</ArticleId><ArticleId IdType="pmc">PMC6313313</ArticleId><ArticleId IdType="pubmed">30501091</ArticleId></ArticleIdList></Reference><Reference><Citation>Pien BC, Saah JR, Miller SE, et al. Use of sentinel laboratories by clinicians to evaluate potential bioterrorism and emerging infections. Clin Infect Dis. 2006;42(9):1311–1324. doi:10.1086/503260</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/503260</ArticleId><ArticleId IdType="pmc">PMC7107841</ArticleId><ArticleId IdType="pubmed">16586392</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevalier MS, Chung W, Smith J, et al. Ebola virus disease cluster in the United States-Dallas county, Texas, 2014. MMWR Morb Mortal Wkly Rep. 2014;63(46):1087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5779510</ArticleId><ArticleId IdType="pubmed">25412069</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. US department of health and human services-biosafety in microbiological and biomedical laboratories. Public Heal Serv. 2009:438</Citation></Reference><Reference><Citation>Long Y, Chang F, Yang F, et al. Biosafety risk assessment and risk control of clinical laboratory in designated hospitals for treating COVID-19 in Chongqing, China. Am J Infect Control. 2022;50(9):999–1005. doi:10.1016/j.ajic.2022.05.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajic.2022.05.028</ArticleId><ArticleId IdType="pmc">PMC9167147</ArticleId><ArticleId IdType="pubmed">35671845</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>